Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy.
Aflibercept
Intravitreal injections
Microperimetry
OCT angiography
Proliferative diabetic retinopathy
Type 2 diabetes
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
05
07
2022
accepted:
26
08
2022
pubmed:
18
9
2022
medline:
18
9
2022
entrez:
17
9
2022
Statut:
ppublish
Résumé
This study assessed retinal nonperfusion area (NPA) changes after anti-VEGF treatment in proliferative diabetic retinopathy (PDR) eyes using swept-source widefield optical coherence tomography angiography (SS-WF OCTA) and investigated the relationships with the microperimetry (MP-1) functional changes observed in the same areas. This was a single-center observational case series. Seven PDR eyes naïve to treatment that received three monthly intravitreal injections of aflibercept were included. All eyes were imaged with SS-WF OCTA and MP-1 at baseline (T0) and 1 month after the third injection (T1). The regions of interest (ROIs) with evidence of NPAs at T0 OCTA images were selected. Qualitative and quantitative [perfusion density (PD) and vessel length density (VLD)] OCTA vascular changes in the selected ROIs between T0 and T1 were compared with the corresponding MP-1 functional changes [mean sensitivity (MS)]. Twenty-five ROIs were selected. In 52% of the ROIs, an improvement in MS was observed at T1, which was associated with qualitative and quantitative improvement in 92.3% of NPAs by OCTA. In 32% of the ROIs, MS worsening was observed at T1, which was associated with qualitative and quantitative worsening in 75% of NPAs by OCTA. Positive correlations between MS and both PD and VLD were found. Fisher's test showed an association between the improvements in MP and VLD. An association between OCTA and MP-1 parameter changes was found. The concomitant functional and morphological improvement in half of the ROIs suggests that anti-VEGF treatment may promote retinal changes that result in a better functional response.
Identifiants
pubmed: 36114830
doi: 10.1007/s40123-022-00568-x
pii: 10.1007/s40123-022-00568-x
pmc: PMC9587173
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2117-2128Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2020 Dec 1;15(12):e0243074
pubmed: 33259557
Eye (Lond). 2020 Dec;34(12):2264-2270
pubmed: 32055020
Ophthalmology. 2019 Dec;126(12):1685-1694
pubmed: 31383483
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):30-34
pubmed: 28114569
Eye Vis (Lond). 2015 Sep 30;2:17
pubmed: 26605370
Ophthalmology. 1991 May;98(5 Suppl):823-33
pubmed: 2062515
Retina. 2019 Mar;39(3):426-434
pubmed: 30664126
Ophthalmology. 1991 May;98(5 Suppl):766-85
pubmed: 2062512
Br J Ophthalmol. 2007 Nov;91(11):1499-503
pubmed: 17504849
Ophthalmology. 2016 Mar;123(3):625-34.e1
pubmed: 26712560
Am J Ophthalmol. 2007 Nov;144(5):755-760
pubmed: 17868632
Saudi J Ophthalmol. 2011 Apr;25(2):131-5
pubmed: 23960914
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT362-70
pubmed: 27409494
JAMA. 2015 Nov 24;314(20):2137-2146
pubmed: 26565927
Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3044-51
pubmed: 16799051
Sci Rep. 2021 Jul 26;11(1):15183
pubmed: 34312425
Ophthalmology. 2017 Jul;124(7):944-952
pubmed: 28318637
J Ophthalmol. 2019 Oct 13;2019:7589841
pubmed: 31737359
Clin Ophthalmol. 2017 Jan 21;11:193-200
pubmed: 28176934
Ophthalmology. 2013 Apr;120(4):795-802
pubmed: 23260261
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Lancet. 2017 Jun 3;389(10085):2193-2203
pubmed: 28494920
Am J Ophthalmol. 2017 Sep;181:149-155
pubmed: 28687219
Retina. 2020 Feb;40(2):322-332
pubmed: 31972803
JAMA Ophthalmol. 2017 Apr 1;135(4):370-376
pubmed: 28301651